NCT06362447

Efficacy of Injectable Gentamicin in Hereditary Ichthyosis

Phase 2 Study Evaluating the Efficacy of Injectable Gentamicin in Hereditary Ichthyosis

• Status: Not Yet Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 26 (estimated)
• Sponsor: University Hospital, Toulouse · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This study will evaluate the efficacy and safety of intravenous gentamicin in congenital ichthyosis due to a non-sens mutation. The primary objective is the severity of scales and erythema at the third month, compared to baseline. Secondary objectives will include: the importance of itching, trans epidermal water loss, cutaneous expression of the targeted protein, the security of the drug and patients' satisfaction.

Detailed description

Congenital ichthyoses represent a group of diseases characterized by disabling cutaneous anomalies (scales and inconstant erythema) often associated with extra cutaneous anomalies that may be severe. The treatment is non curative and symptomatic, including local treatments (ie. emollients). Oral retinoids may be helpful in moderate to severe forms. There is a huge need for novel therapies, ideally targeting the molecular defect. Gentamicin may be a novel therapeutic option for congenital ichthyosis. Apart its antimicrobial effect, gentamicin can achieve stop codon readthrough and produce full-length protein. In this study, gentamicin (10 mg/kg) will be administrated once weekly for 3 months. The study will include monthly visits, a follow-up visit 3 months after the stopping the drug and an end-of-study visit 3 months after the follow-up visit. Kidney and hearing functions will be assessed regularly.

Conditions

• Ichthyosis

Interventions

Type	Name	Description
DRUG	Gentamicin Injectable Solution	Gentamicin (10 mg/kg) will be administrated once weekly for 3 months

Timeline

• Start date: 2024-09-01
• Primary completion: 2026-04-01
• Completion: 2027-04-01
• First posted: 2024-04-12
• Last updated: 2024-09-05

Locations

2 sites across 1 country: France